Consistently, a previous meta-analysis by Zhang et al. [54] reported that TUBB3 was a biomarker for the sensitivity of paclitaxel/vinorebine-based chemotherapy in patients with NSCLC. The gene discussed is TUBB3; the disease is non-small cell lung carcinoma.